Harvard Medical School and Cancer Center at Beth Israel Deaconess Medical Center
Postdoctoral position available beginning spring/summer 2021
Our lab studies how cancer cells develop drug resistance, and more specifically, how the tumor microenvironment, particularly cancer-associated fibroblasts, provide support and protection for the tumor cells. Our aim is to develop better treatment strategies to overcome this tumor microenvironment mediated drug resistance.
To investigate these topics we utilize mouse models, established cancer cells lines, patient-derived organoids, and patient-derived cancer associated fibroblasts. We use co-culture systems to understand how stromal and epithelial cells communicate with each other, and have also adopted the use of organoids for larger scale methodologies, such as proteomics, metabolomics and RNA-seq experiments to gain insight into multiple mechanisms by which stromal cells and cancer cells interact to drive drug resistance.
Our laboratory is located in the Longwood medical area next to Harvard Medical School, at the Beth Israel Deaconess Medical Center. Our laboratory is also part of the BROAD Institute, Dana-Farber/Harvard Cancer Center and Harvard Stem Cell Institute. We have several established collaborations within groups in the Harvard Medical School, as well as in MIT, Children’s Hospital and MD Anderson, among others. This environment provides unique opportunities for performing cutting-edge science, training in state-of-the-art technologies, forming new collaborations and networks, and developing new technologies.
We are looking for highly motivated individual(s) who have recently finished their PhD, with excellent communication and critical thinking skills, and who are able to work as part of a team. Training in cell biology, biochemistry and molecular biology, and basic understanding of cell signaling networks is highly desired.
At this time we are particularly looking for individuals interested in joining our NIH and ACS funded projects on uncovering mechanisms by which stromal cells in the pancreas stimulate chemoresistance in pancreatic cancer.
For more information, please visit our lab web page: http://www.muranenlab.org
Or refer to the relevant publications: Muranen et al. Cancer Cell 2012, Muranen at al. Cancer Research 2016, Muranen et al. Nature Communications 2017, and Kozlova et al 2020 Trends in Pharmacological Sciences.
Please send a cover letter with short description of your research interests and previous experience, current CV, and names of three references to tmuranen(at)bidmc.harvard.edu.